GW Pharmaceuticals to Present at the Cowen and Company 37th Annual Healthcare Conference on Wednesday, 8 March, 2017
March 02 2017 - 12:00PM
GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform, today announced that Justin Gover, GW’s Chief
Executive Officer, will present at the Cowen and Company 37th
Annual Healthcare Conference on Wednesday, 8 March, 2017 at 8:40
a.m. EST at the Boston Marriott Copley Place, Boston.
A live audio webcast of the presentation will be
available through GW’s corporate website at www.gwpharm.com on the
Investors section under Events & Presentations. A replay will
be available soon after the live presentation.
About GW Pharmaceuticals
plc
Founded in 1998, GW is a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from its proprietary cannabinoid product
platform in a broad range of disease areas. GW is advancing an
orphan drug program in the field of childhood epilepsy with a focus
on Epidiolex® (cannabidiol), which is in Phase 3 clinical
development for the treatment of Dravet syndrome, Lennox-Gastaut
syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW
commercialized the world’s first plant-derived cannabinoid
prescription drug, Sativex® (nabiximols), which is approved for the
treatment of spasticity due to multiple sclerosis in 31 countries
outside the United States. The Company has a deep pipeline of
additional cannabinoid product candidates which includes compounds
in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For
further information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc
Stephen Schultz, VP Investor Relations (U.S.)
917 280 2424 / 401 500 6570
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Sep 2023 to Sep 2024